Imperial College London
Alternate

Dr. Ramzi Y Khamis MB ChB PhD FESC FRCP

Faculty of Medicine, National Heart & Lung Institute

Reader in Cardiology
 
 
 
//

Contact

 

+44 (0)20 7594 6842r.khamis

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{van:2018:10.1016/j.ebiom.2018.08.023,
author = {van, den Berg VJ and Haskard, DO and Fedorowski, A and Hartley, A and Kardys, I and Caga-Anan, M and Akkerhuis, KM and Oemrawsingh, RM and van, Geuns RJ and de, Jaegere P and van, Mieghem N and Regar, E and Ligthart, JMR and Umans, VAWM and Serruys, PW and Melander, O and Boersma, E and Khamis, RY},
doi = {10.1016/j.ebiom.2018.08.023},
journal = {EBioMedicine},
pages = {63--72},
title = {IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3).},
url = {http://dx.doi.org/10.1016/j.ebiom.2018.08.023},
volume = {36},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Certain immunoglobulins (Ig) are proposed to have protective functions in atherosclerosis. OBJECTIVES: We tested whether serum levels of IgG and IgM autoantibodies against malondialdehyde low density lipoprotein (MDA-LDL) are associated with clinical coronary heart disease (CHD) and unfavorable plaque characteristics. METHODS: NORDIL was a prospective study investigating adverse cardiovascular outcomes in hypertensive patients. IBIS-3 analyzed lesions in a non-culprit coronary artery with <50% stenosis using radiofrequency intravascular ultrasound (RF-IVUS) and near-infrared spectroscopy (NIRS). Imaging was repeated after a median of 386days on rosuvastatin. Associations of antibodies with incident CHD and imaging parameters were assessed in the two sub-studies respectively. FINDINGS: From 10,881 NORDIL patients, 87 had serum sampled at baseline and developed CHD over 4.5years, matched to 227 controls. Higher titers of IgM anti-MDA-LDL had a protective effect on adverse outcomes, with odds ratio 0.29 (0.11, 0.76; p=0.012; p=0.016 for trend). Therefore, the effect was explored at the lesional level in IBIS-3. 143 patients had blood samples and RF-IVUS measurements available, and NIRS was performed in 90 of these. At baseline, IgM anti-MDA-LDL levels had a strong independent inverse relationship with lesional necrotic core volume (p=0.027) and percentage of plaque occupied by necrotic core (p=0.011), as well as lipid core burden index (p=0.024) in the worst 4mm segment. INTERPRETATION: Our study supports the hypothesis that lower circulating levels of IgM anti-MDA-LDL are associated with clinical CHD development, and for the first time relates these findings to atherosclerotic plaque characteristics that are linked to vulnerability.
AU  - van,den Berg VJ
AU  - Haskard,DO
AU  - Fedorowski,A
AU  - Hartley,A
AU  - Kardys,I
AU  - Caga-Anan,M
AU  - Akkerhuis,KM
AU  - Oemrawsingh,RM
AU  - van,Geuns RJ
AU  - de,Jaegere P
AU  - van,Mieghem N
AU  - Regar,E
AU  - Ligthart,JMR
AU  - Umans,VAWM
AU  - Serruys,PW
AU  - Melander,O
AU  - Boersma,E
AU  - Khamis,RY
DO  - 10.1016/j.ebiom.2018.08.023
EP  - 72
PY  - 2018///
SN  - 2352-3964
SP  - 63
TI  - IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3).
T2  - EBioMedicine
UR  - http://dx.doi.org/10.1016/j.ebiom.2018.08.023
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30131305
UR  - http://hdl.handle.net/10044/1/65016
VL  - 36
ER  -
Download